Asset Details
Do you wish to reserve the book?
Cost-benefit analysis of a trifocal intraocular lens versus a monofocal intraocular lens in South Korea
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cost-benefit analysis of a trifocal intraocular lens versus a monofocal intraocular lens in South Korea
Do you wish to request the book?
Cost-benefit analysis of a trifocal intraocular lens versus a monofocal intraocular lens in South Korea
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cost-benefit analysis of a trifocal intraocular lens versus a monofocal intraocular lens in South Korea
2025
Overview
This study aimed to estimate the net monetary benefit (NMB) of trifocal intraocular lenses (IOL) versus monofocal IOL in South Korea according to patient age. A hybrid model with a short-term decision tree, followed by a lifetime Markov model, was developed. The study considered patients aged 45–75 years old. Probabilities of visual disturbances and wearing glass were obtained from a clinical trial of trifocal IOL (NCT03280108). The analysis considered medical and glass costs. Utility values for each age were adopted from previous studies. The incremental QALY was mapped to the patient’s willingness to pay (WTP) thresholds of gross domestic product per capita (GDP; $32,310), $23,000, and $15,000 per QALY gain to estimate the NMB. Trifocal IOL incurred higher costs but resulted in increased QALYs in all age groups. Under the WTP of $15,000, the NMB ranged from $694 at 75 to $6,880 at 45. The NMB with GDP was from $6,731 at 75 to $19,590 at 45. Using trifocal IOL can enhance the quality of life compared to no presbyopia correction with monofocal IOL in patients who want to correct presbyopia. Younger patients have greater economic benefits. Thus, trifocal IOLs are a worthy treatment option considering age and WTP.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
